RU2527151C2 - Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ - Google Patents

Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ Download PDF

Info

Publication number
RU2527151C2
RU2527151C2 RU2009137779/04A RU2009137779A RU2527151C2 RU 2527151 C2 RU2527151 C2 RU 2527151C2 RU 2009137779/04 A RU2009137779/04 A RU 2009137779/04A RU 2009137779 A RU2009137779 A RU 2009137779A RU 2527151 C2 RU2527151 C2 RU 2527151C2
Authority
RU
Russia
Prior art keywords
compound
formula
kinase
disease
cancer
Prior art date
Application number
RU2009137779/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009137779A (ru
Inventor
Джон ВУДХЕД Стивен
Чарлз РИС Дейвид
ФРЕДЕРИКСОН Мартин
Мерриом ГРИМШО Кайла
Original Assignee
Астекс Терапьютикс Лимитед
Дзе Инститьют Оф Кэнсе Рисёч Ройал Кэнсе Хоспитал
Кэнсе Рисёч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астекс Терапьютикс Лимитед, Дзе Инститьют Оф Кэнсе Рисёч Ройал Кэнсе Хоспитал, Кэнсе Рисёч Текнолоджи Лимитед filed Critical Астекс Терапьютикс Лимитед
Publication of RU2009137779A publication Critical patent/RU2009137779A/ru
Application granted granted Critical
Publication of RU2527151C2 publication Critical patent/RU2527151C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
RU2009137779/04A 2007-03-14 2008-03-14 Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ RU2527151C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89475207P 2007-03-14 2007-03-14
GB0704932.3 2007-03-14
GBGB0704932.3A GB0704932D0 (en) 2007-03-14 2007-03-14 Pharmaceutical compounds
US60/894,752 2007-03-14
PCT/GB2008/050180 WO2008110846A2 (en) 2007-03-14 2008-03-14 Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases

Publications (2)

Publication Number Publication Date
RU2009137779A RU2009137779A (ru) 2011-05-10
RU2527151C2 true RU2527151C2 (ru) 2014-08-27

Family

ID=38008428

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009137779/04A RU2527151C2 (ru) 2007-03-14 2008-03-14 Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ

Country Status (23)

Country Link
US (2) US20100113551A1 (https=)
EP (2) EP2134339B1 (https=)
JP (2) JP2010521446A (https=)
KR (1) KR20100014720A (https=)
CN (1) CN101686965B (https=)
AU (1) AU2008224657B2 (https=)
BR (1) BRPI0808802A2 (https=)
CA (1) CA2679878A1 (https=)
CY (1) CY1115877T1 (https=)
DK (1) DK2134339T3 (https=)
ES (1) ES2511817T3 (https=)
GB (1) GB0704932D0 (https=)
HR (1) HRP20141034T1 (https=)
IL (1) IL200822A (https=)
MX (1) MX2009009874A (https=)
NZ (1) NZ579341A (https=)
PL (1) PL2134339T3 (https=)
PT (1) PT2134339E (https=)
RS (1) RS53580B1 (https=)
RU (1) RU2527151C2 (https=)
SI (1) SI2134339T1 (https=)
WO (1) WO2008110846A2 (https=)
ZA (1) ZA200906303B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657832C1 (ru) * 2017-06-07 2018-06-15 федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" Антидиабетическое средство

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418078A8 (pt) 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
EP4125910B1 (en) * 2020-03-25 2025-11-12 Woolsey Pharmaceuticals, Inc. Rho kinase inhibitors for treating frontotemporal dementia
CN111707830B (zh) * 2020-07-16 2023-08-15 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肺损害中的应用
WO2022125056A1 (en) 2020-12-07 2022-06-16 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136830A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
RU2006126789A (ru) * 2003-12-23 2008-01-27 Астекс Терапьютикс Лимитед (Gb) Производные пиразола в качестве модуляторов протеинкиназы

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2046628A1 (en) 1989-02-08 1990-08-09 Dee W. Brooks 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5049570A (en) 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5532356A (en) 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP2000507593A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
GB2339298B (en) 1996-04-30 2000-05-10 Eastman Kodak Co Use of pyrazolone image dye-forming couplers for enhancing light stability
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
GB9700555D0 (en) 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU759772B2 (en) 1998-01-29 2003-05-01 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6503905B1 (en) 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
CA2372044A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
DE60226154T2 (de) 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
FR2830192B1 (fr) 2001-09-28 2004-08-20 Oreal Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
RS52392B (sr) 2002-02-14 2013-02-28 Pharmacia Corporation Supstituisani piridinoni kao modulatori p38 map kinaze
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
ES2575354T3 (es) 2002-04-08 2016-06-28 Boston Scientific Scimed, Inc. Dispositivos y procedimientos de saciedad
AU2003223708A1 (en) 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
ES2385378T3 (es) 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
CA2498046A1 (en) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri Opiate analogs selective for the delta-opioid receptor
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
CA2530389A1 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
US20050192314A1 (en) 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
BRPI0418078A8 (pt) 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
GB2427406A (en) 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006126789A (ru) * 2003-12-23 2008-01-27 Астекс Терапьютикс Лимитед (Gb) Производные пиразола в качестве модуляторов протеинкиназы
WO2006136830A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657832C1 (ru) * 2017-06-07 2018-06-15 федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" Антидиабетическое средство

Also Published As

Publication number Publication date
KR20100014720A (ko) 2010-02-10
SI2134339T1 (sl) 2014-12-31
PL2134339T3 (pl) 2015-04-30
CN101686965A (zh) 2010-03-31
NZ579341A (en) 2012-08-31
JP2010521446A (ja) 2010-06-24
US20110269808A1 (en) 2011-11-03
IL200822A (en) 2016-09-29
WO2008110846A2 (en) 2008-09-18
DK2134339T3 (da) 2014-11-03
RU2009137779A (ru) 2011-05-10
HRP20141034T1 (hr) 2014-12-19
US20100113551A1 (en) 2010-05-06
RS53580B1 (sr) 2015-02-27
PT2134339E (pt) 2014-11-03
JP2015028033A (ja) 2015-02-12
BRPI0808802A2 (pt) 2017-05-02
ES2511817T3 (es) 2014-10-23
GB0704932D0 (en) 2007-04-25
US8497294B2 (en) 2013-07-30
EP2433632A1 (en) 2012-03-28
CN101686965B (zh) 2014-09-17
AU2008224657B2 (en) 2014-06-26
HK1133828A1 (en) 2010-04-09
CA2679878A1 (en) 2008-09-18
AU2008224657A1 (en) 2008-09-18
WO2008110846A3 (en) 2009-03-05
IL200822A0 (en) 2010-05-17
EP2134339B1 (en) 2014-09-17
ZA200906303B (en) 2015-08-26
EP2134339A2 (en) 2009-12-23
MX2009009874A (es) 2009-09-24
CY1115877T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
RU2527151C2 (ru) Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ
CN113365994B (zh) 哒嗪基噻唑甲酰胺类化合物
EP3719018B1 (en) Purine and deazapurine derivatives as pharmaceutical compounds
EP3939979A1 (en) Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
BR112015028501B1 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
JP2010522722A (ja) プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
CN102971324A (zh) mTOR选择性激酶抑制剂
CN108699080B (zh) 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
CN104557871B (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN110475771B (zh) Ck1和/或irak1抑制剂、药物组合物和用于癌症治疗的治疗应用
JP2026503519A (ja) ｍＰＴＰの阻害剤
AU2016213031B2 (en) Novel salt of fused pyrimidine compound and crystal thereof
CN112125908A (zh) Cdk激酶抑制剂、其制备方法、药物组合物和应用
CN101489559A (zh) 作为药物化合物的嘌呤和脱氮嘌呤衍生物
CA3130478A1 (en) Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient
HK1133828B (en) Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
TW202547480A (zh) 可用於治療增殖性疾病或病症之化合物及組合物
HK40059656A (en) Pyridazinyl thiazolecarboxamide compound
HK40084227A (zh) 哒嗪基噻唑甲醯胺类化合物
KR101672975B1 (ko) 알로스테릭 ｐｌｋ1-ｐｂｄ 저해활성을 가지는 고리형 포스포펩티드 화합물
EP3212649A2 (en) Compounds and uses thereof
TW201309701A (zh) ２－氧基取代８－側氧基二氫嘌呤衍生物

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170315